Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients

Nature Medicine

Volumn 2, Issue 7, 1996, Pages 811-814

  Aas, Turid ^a   Børresen, Anne Lise ^c   Geisler, Stephanie ^b   Smith Sørensen, Birgitte ^c   Johnsen, Hilde ^c   Varhaug, Jan E ^a   Akslen, Lars A ^a   Lønning, Per E ^b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; MUTATION; PRIORITY JOURNAL;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; TREATMENT OUTCOME;

EID: 0029956081     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0796-811     Document Type: Article

References (18)

1. Kerr, J.F.R., Winterford, C.M. & Harmon, B.V. Apoptosis: Its significance in cancer and cancer therapy. Cancer 73, 2013-2026 (1994).
2. Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957-967 (1993).
3. Lowe, S.W. et al. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810 (1994).
4. Rusch, V. et al. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res. 55, 5038-5042 (1995).
5. Bergh, J., Norberg, T., Sjögren, S., Lindgren, A. & Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med. 1, 1029-1034 (1995).
6. Børresen, A.L. et al. TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosom. Cancer 14, 71-75 (1995).
7. Allred, D.C. et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst. 85, 200-206 (1993).
8. Jansson, T. et al. p53 status predicts survival in breast cancer patients treated with/without postoperative radiotherapy: A novel hypothesis based on clinical findings. J. Clin. Oncol. 13, 2745-2751 (1995).
9. Stål, O. et al. p53 expression and the result of adjuvant therapy of breast cancer. Acta Oncol. 34, 767-770 (1995).
10. Clavel, M. & Catimel, G. Breast Cancer: Chemotherapy in the treatment of advanced disease. Eur. J. Cancer 29A, 598-604 (1993).
11. Gundersen, S., Hannisdal, E., Lundgren, S. & Wist, E. Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer: A randomised study. Eur. J. Cancer 30A, 1775-1778 (1994).
12. Hayward, J.L. et al. Assessment of response to therapy in advanced breast cancer. Br. J. Cancer 35, 292-298 (1977).
13. Andersen, T.I. & Borresen, A.-L. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Diagn. Molec. Pathol. 4, 203-211 (1995).
14. Preudhomme, C. et al. Relationship between p53 gene mutation and multidrug resistance (mdr1) gene expression in myelodysplastic syndromes. Leukemia 7, 1888-1889 (1993).
15. Pocard, M. et al. Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Oncogene 12, 875-882 (1996).
16. Cho, Y., Gorina, S., Jeffrey, P.D. & Pavletich, N.P. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265, 346-355 (1994).
17. Dixon, W.J. BMDP statistical software. (University of California Press, 1995).
18. Elston, C.W. & Ellis, I.O. Pathological prognostic factors in breast cancer. I. The value of histological grading in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19, 403-410 (1991).